Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 6/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | FBP1 | P09467 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | CXCR5 | P32302 | 1/20 | 0.35 |
| ▸ | APLNR | P35414 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | CCR6 | P51684 | 1/20 | 0.35 |
| ▸ | GFER | P55789 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | CRHBP | P24387 | 1/20 | 0.35 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 4-Nitrotoluene SCHEMBL11816835 | 0.74 | ACHE (0.90) | ACHEHSD17B10TDP1TSHRALDH1A1 | |
| SCHEMBL1870196 | 0.72 | ALOX15 (0.44) | ACHEHSD17B10TDP1FBP1GAA | |
| 4-Nitrotoluene SCHEMBL73252 | 0.72 | ACHE (1.00) | ACHEHSD17B10TDP1TSHRKMT2A | |
| SCHEMBL13176834 | 0.72 | ACHE (0.56) | ACHEHSD17B10TDP1FBP1GAA | |
| SCHEMBL28579476 | 0.72 | ACHE (0.56) | ACHEHSD17B10TDP1FBP1GAA | |
| 4-Nitrotoluene SCHEMBL2484690 | 0.72 | ACHE (1.00) | ACHEHSD17B10TDP1TSHRKMT2A | |
| 4-Nitrotoluene SCHEMBL9402408 | 0.70 | ACHE (0.95) | ACHEHSD17B10TDP1TSHRKMT2A | |
| 4-Nitrotoluene SCHEMBL28533556 | 0.70 | ACHE (0.95) | ACHEHSD17B10TDP1TSHRKMT2A | |
| 4-Nitrotoluene SCHEMBL9734611 | 0.70 | ACHE (0.95) | ACHEHSD17B10TDP1TSHRKMT2A | |
| 4-Nitrotoluene SCHEMBL6751959 | 0.70 | ACHE (0.95) | ACHEHSD17B10TDP1TSHRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115772105-B | Synthesis method of 4-nitroanisole | 厦门大学 | 2024-06-11 | — | — | CN | disclosed |
| CN-115772105-A | Synthesis method of 4-nitroanisole | 厦门大学 | 2023-03-10 | — | — | CN | disclosed |
| US-8815895-B2 | Mediators of hedgehog signaling pathways, compositions and uses related hereto | CURIS, INC. (US) | 2014-08-26 | — | — | US | disclosed |
| EP-1807074-B1 | MEDIATORS OF HEDGEHOG SIGNALING PATHWAYS, COMPOSITIONS AND USES RELATED THERETO | CURIS INC (US) | 2013-10-23 | — | — | EP | disclosed |
| US-20120283258-A1 | MEDIATORS OF HEDGEHOG SIGNALING PATHWAYS, COMPOSITIONS AND USES RELATED HERETO | CURIS, INC. (US) | 2012-11-08 | — | — | US | disclosed |
| US-8168653-B2 | Mediators of hedgehog signaling pathways, compositions and uses related thereto | CURIS, INC. (US) | 2012-05-01 | — | — | US | disclosed |
| US-20100317660-A1 | Mediators of hedgehog signaling pathways, compositions and uses related thereto | GUICHERIT OIVIN M | 2010-12-16 | — | — | US | disclosed |
| US-7816369-B2 | hedgehog genes antagonists such as N-[5-(1H-benzimidazol-2-yl)-6-chloropyridin-3-yl]-2-methyl-6-(trifluoromethyl)pyridine-3-carboxamide, used as anticarcinogenic or antitumor agents | CURIS, INC. (US) | 2010-10-19 | — | — | US | disclosed |
| US-20090012082-A1 | hedgehog genes antagonists such as N-[5-(1H-benzimidazol-2-yl)-6-chloropyridin-3-yl]-2-methyl-6-(trifluoromethyl)pyridine-3-carboxamide, used as anticarcinogenic or antitumor agents | CURIS, INC. (US) | 2009-01-08 | — | — | US | disclosed |
| CN-101265224-A | Method for preparing 4-trifluoromethylsulfanyl aniline | JINTAN LINGYUN CHEMICAL FACTOR (CN) | 2008-09-17 | — | — | CN | disclosed |
| EP-0880504-B1 | HETEROCYCLO-SUBSTITUTED IMIDAZOLES FOR THE TREATMENT OF INFLAMMATION | SEARLE & CO (US) | 2003-04-02 | — | — | EP | disclosed |
| US-20030036557-A1 | Heterocyclo-substituted imidazoles for the treatment of inflammation | G.D. SEARLE & CO. | 2003-02-20 | — | — | US | disclosed |
| EP-0772600-B1 | 1,2-SUBSTITUTED IMIDAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | SEARLE & CO (US) | 2002-09-18 | — | — | EP | disclosed |
| EP-1193265-A2 | A process for the preparation of 4-[2-(aryl or heterocyclo)-1H-imidazol-1-yl]benzenesulfonamides | G.D. Searle & Co. (US) | 2002-04-03 | — | — | EP | disclosed |
| EP-0880504-A1 | HETEROCYCLO-SUBSTITUTED IMIDAZOLES FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1998-12-02 | — | — | EP | disclosed |
| WO-1997027181-A1 | HETEROCYCLO-SUBSTITUTED IMIDAZOLES FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1997-07-31 | — | — | WO | disclosed |
| EP-0772600-A1 | 1,2-SUBSTITUTED IMIDAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1997-05-14 | — | — | EP | disclosed |
| US-5616601-A | 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation | GD SEARLE & CO (US) | 1997-04-01 | — | — | US | disclosed |
| WO-1996003388-A1 | 1,2-SUBSTITUTED IMIDAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1996-02-08 | — | — | WO | disclosed |
| EP-0051773-A1 | Penicillins, their salts, process for their preparation and pharmaceutical compositions containing them | Dr. Karl Thomae GmbH (DE) | 1982-05-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030036557-A1 | Heterocyclo-substituted imidazoles for the treatment of inflammation | HCK, IL4I1, AHR | ACHE 3072/4885HSD17B10 346/4885TDP1 4383/4885 |
| US-20100317660-A1 | Mediators of hedgehog signaling pathways, compositions and uses related thereto | SHH, SMO, GLI1 | ACHE 4845/4885HSD17B10 3434/4885TDP1 4734/4885 |
| US-20090012082-A1 | hedgehog genes antagonists such as N-[5-(1H-benzimidazol-2-yl)-6-chloropyridin-3-yl]-2-methyl-6-(trifluoromethyl)pyridine-3-carboxamide, used as anticarcinogenic or antitumor agents | GLI1, SHH, SMO | ACHE 4841/4885HSD17B10 3765/4885TDP1 4365/4885 |
| US-20120283258-A1 | MEDIATORS OF HEDGEHOG SIGNALING PATHWAYS, COMPOSITIONS AND USES RELATED HERETO | SHH, SMO, GLI1 | ACHE 4846/4885HSD17B10 3392/4885TDP1 4698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.